Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients.

Ghanizada H, Al-Karagholi MA, Walker CS, Arngrim N, Rees T, Petersen J, Siow A, Mørch-Rasmussen M, Tan S, O'Carroll SJ, Harris P, Skovgaard LT and 8 more

Show all authors

Jørgensen NR, Brimble M, Waite JS, Rea BJ, Sowers LP, Russo AF, Hay DL, Ashina M

Annals of neurology8 Apr 2021Cited by 92 (Europe PMC)

PMID33772845PMCIDPMC8486152DOI10.1002/ana.26072PepBankPUB-33772845

Source link PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialSafety outcome
In patients with migraine without aura, headache occurred in 88% after pramlintide versus 97% after CGRP, without a significant difference.
In plain wordsIn migraine patients, headache frequency did not differ significantly between pramlintide and CGRP.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeHeadache
Study
n: not reported in source
Comparator
Human αCGRP
Outcome group
Pain · Nervous system and cognition
Studied dose
Dose not stated · infusionAs given in this study (human).
Measurements
Patients with headache
88%
after pramlintide infusion
Patients with headache
97%
after CGRP infusion
Source sentences
Summary
Thirty patients (88%) developed headache after pramlintide infusion, compared to 33 (97%) after CGRP (p = 0.375).
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-six migraine without aura patients were enrolled in a randomized, double-blind, 2-way, crossover, positive-controlled clinical trial study to receive infusion of an amylin analogue pramlintide or human αCGRP on 2 different experimental days.
Report a problemFND-3377284501
02HumanRandomized controlled trialSafety outcome
In patients with migraine without aura, migraine-like attacks occurred in 41% after pramlintide versus 56% after CGRP, without a significant difference.
In plain wordsIn migraine patients, migraine-like attack frequency did not differ significantly between pramlintide and CGRP.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeMigraine-like attacks
Study
n: not reported in source
Comparator
Human αCGRP
Outcome group
Pain · Nervous system and cognition
Studied dose
Dose not stated · infusionAs given in this study (human).
Measurements
Patients with migraine-like attacks
41%
after pramlintide infusion
Patients with migraine-like attacks
56%
after CGRP infusion
Source sentences
Summary
Fourteen patients (41%) developed migraine-like attacks after pramlintide infusion, compared to 19 patients (56%) after CGRP (p = 0.180).
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-six migraine without aura patients were enrolled in a randomized, double-blind, 2-way, crossover, positive-controlled clinical trial study to receive infusion of an amylin analogue pramlintide or human αCGRP on 2 different experimental days.
Report a problemFND-3377284502
03HumanRandomized controlled trialOther
In migraine patients, pramlintide-induced and CGRP-induced attacks had similar clinical characteristics.
In plain wordsIn migraine patients, attacks after pramlintide and CGRP had similar characteristics.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeAttack characteristics
Study
n: not reported in source
Comparator
Human αCGRP
Outcome group
Pain · Nervous system and cognition
Studied dose
Dose not stated · infusionAs given in this study (human).
Source sentences
Summary
The pramlintide-induced migraine-like attacks had similar clinical characteristics to those induced by CGRP.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-six migraine without aura patients were enrolled in a randomized, double-blind, 2-way, crossover, positive-controlled clinical trial study to receive infusion of an amylin analogue pramlintide or human αCGRP on 2 different experimental days.
Report a problemFND-3377284503
04HumanRandomized controlled trialOther
In migraine patients, vascular parameters differed between pramlintide and CGRP treatment.
In plain wordsIn migraine patients, vascular measurements differed between pramlintide and CGRP treatment.
Peptide
Pramlintide (Symlin)
Outcome
Direction not reportedVascular parameters
Study
n: not reported in source
Comparator
Human αCGRP
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
Dose not stated · infusionAs given in this study (human).
Source sentences
Summary
There were differences between treatments in vascular parameters.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-six migraine without aura patients were enrolled in a randomized, double-blind, 2-way, crossover, positive-controlled clinical trial study to receive infusion of an amylin analogue pramlintide or human αCGRP on 2 different experimental days.
Report a problemFND-3377284504
05LabIn vitro (cells)Mechanism
In human receptor pharmacology studies, an amylin receptor likely mediated pramlintide effects rather than the canonical CGRP receptor.
In plain wordsIn lab tests, an amylin receptor likely mediated pramlintide effects rather than the canonical CGRP receptor.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableReceptor mediation
Study
humann: not reported in source
Human receptor pharmacology studies
Comparator
Canonical CGRP receptor
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
Human receptor pharmacology studies showed that an amylin receptor likely mediates these pramlintide-provoked effects, rather than the canonical CGRP receptor.
Report a problemFND-3377284505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 not yet recruiting · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingNot applicableNCT07340775

Hypersensitivity to Amylin in Post-Traumatic Headache

Danish Headache Centern = 21est. Feb 2026 to est. Dec 2028

Headache Disorders, Secondary · Brain Diseases · Headache Disorders · Nervous System Diseases · Central Nervous System Diseases · Neurologic Manifestations · Signs and Symptoms · Pathological Conditions, Signs and Symptoms · Post-Traumatic Headache · Pain · Peptide Hormones · Hormones · Hormones, Hormone Substitutes, and Hormone Antagonists · Peptides · Amino Acids, Peptides, and Proteins · Amylin · Pramlintide

Trial page ClinicalTrials.govUpdated 14 Jan 2026

Not yet recruitingNot applicableNCT07340788

Amylin-Induced Migraine Attacks Without Aura

Danish Headache Centern = 21est. Feb 2026 to est. 30 Oct 2028

Headache Disorders, Primary · Headache Disorders · Brain Diseases · Nervous System Diseases · Central Nervous System Diseases · Neurologic Manifestations · Signs and Symptoms · Pathological Conditions, Signs and Symptoms · Migraine Disorders · Headache · Pain · Peptide Hormones · Hormones · Hormones, Hormone Substitutes, and Hormone Antagonists · Peptides · Amino Acids, Peptides, and Proteins · Amylin · Pramlintide

Trial page ClinicalTrials.govUpdated 14 Jan 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.